Roundtable stakeholders: Biomarkers – Co-creating the Framework

The roundtable focused on the formation of a framework for the introduction and reimbursement of biomarkers in Greece and the presentation of a relevant roadmap from the General Secretary of the Greek Ministry of Health, Mr. Aris Angelis.

The event hosted representatives from all the relevant oncology stakeholders, including state officials and policy makers, health professionals, as well as research, university and industry representatives.

The commitment of the current government towards the implementation of a new national framework for the introduction and reimbursement of biomarkers in oncology has created a very positive momentum for the much-needed reforms that will ensure equal access for patients to new state-of-the-art innovative therapies and precision medicine.

The event started with a special presentation by Mr. Christos Tsagkaris, a member of the Board of Directors of the European Union Cancer Mission. His presentation, entitled “Perspectives of the EU Cancer Mission on Biomarkers in Oncology”, focused on the support provided by the Cancer Mission on member states for the improved access of oncology patients to innovation.

Mr. Aris Angelis, General Secretary of the Ministry of Health unveiled the “Shaping the Future of Biomarkers: A Roadmap for a New National Framework” The roadmap aims to support the introduction and reimbursement of innovative biomarkers within the Greek healthcare system, which will be a vital step forward for cancer patient care and precision medicine in Greece.

The roadmap comprises a detailed plan for the establishment of a framework that will include a structured process of evaluation, pricing, and the reimbursement of updated biomarkers by the Greek healthcare system, aiming to improve the clinical effectiveness and the economic efficiency of the National Health System. More specifically the road map includes:

  • a Budget Impact analysis for biomarkers, which focuses on the costs and economic benefits that will arise from their integration into the healthcare system
  • the leverage of funding resources and opportunities
  • the initiation of a flexible legislative framework that will encompass procedures for the compensation and the regular updating of the list of biomarkers, taking into account the latest developments in medical research and the unmet medical needs.

Downloads:
Aris Angelis – “Shaping the Future of Biomarkers: A Roadmap for a New National Framework” (in Greek)
Christos Tsagaris – “Perspectives of the EU Cancer Mission on Biomarkers in Oncology”